A Review of Recent Improvements, Developments, Effects, and Challenges on Using Phase-Change Materials in Concrete for Thermal Energy Storage and Release

Most concrete employs organic phase change materials (PCMs), although there are different types available for more specialised use. Organic PCMs are the material of choice for concrete due to their greater heat of fusion and lower cost in comparison to other PCMs. Phase transition materials are an example of latent heat storage materials (LHSMs) that may store or release thermal energy at certain temperatures. A phase transition occurs when a solid material changes from a solid state to a liquid state and back again when heat is added or removed. It is common knowledge that adding anything to concrete, including PCMs, will affect its performance. The goal of this review is to detail the ways in which PCMs affect certain concrete features. This overview also looks into the current challenges connected with employing PCMs in concrete. The review demonstrates a number of important findings along with the possible benefits that may pave the way for more research and broader applications of PCMs in construction. More importantly, it has been elucidated that the optimum PCM integrated percentage of 40% has doubled the quantity of thermal energy stored and released in concrete. Compared to conventional concrete, the macro-encapsulated PCMs showed thermal dependability, chemical compatibility, and thermal stability due to delaying temperature peaks. Furthermore, the maximum indoor temperature decreases by 1.85 °C and 3.76 °C in the test room due to the addition of 15% and 30% PCM composite, respectively. Last but not least, incorporating microencapsulated PCM has shown a positive effect on preventing freeze-thaw damage to concrete roads

Recent Advances on The Applications of Phase Change Materials in Cold Thermal Energy Storage: A Critical Review

Cold thermal energy storage (CTES) based on phase change materials (PCMs) has shown great promise in numerous energy-related applications. Due to its high energy storage density, CTES is able to balance the existing energy supply and demand imbalance. Given the rapidly growing demand for cold energy, the storage of hot and cold energy is emerging as a particularly attractive option. The main purpose of this study is to provide a comprehensive overview of the current research progress on the utilisation of PCMs in CTES. The greatest difficulties associated with using PCMs for CTES are also examined in this overview. In this regard, a critical evaluation of experimental and numerical studies of the heat transfer properties of various fundamental fluids using PCMs is conducted. Specifically, several aspects that affect the thermal conductivity of PCMs are investigated. These factors include nanoparticle-rich PCM, a form of encapsulated PCM, solids volume percentage, and particle size. Discussions focus on observations and conclusions are drawn from conducted studies on PCMs used in CTES. Based on the findings of this study, a set of plausible recommendations are made for future research initiatives

Hydrolysis optimization and characterization study of preparing fatty acids from Jatropha curcas seed oil

<p>Abstract</p> <p>Background</p> <p>Fatty acids (FAs) are important as raw materials for the biotechnology industry. Existing methods of FAs production are based on chemical methods. In this study potassium hydroxide (KOH)-catalyzed reactions were utilized to hydrolysis <it>Jatropha curcas </it>seed oil.</p> <p>Results</p> <p>The parameters effect of ethanolic KOH concentration, reaction temperature, and reaction time to free fatty acid (FFA%) were investigated using D-Optimal Design. Characterization of the product has been studied using Fourier transforms infrared spectroscopy (FTIR), gas chromatography (GC) and high performance liquid chromatography (HPLC). The optimum conditions for maximum FFA% were achieved at 1.75M of ethanolic KOH concentration, 65°C of reaction temperature and 2.0 h of reaction time.</p> <p>Conclusions</p> <p>This study showed that ethanolic KOH concentration was significant variable for <it>J. curcas </it>seed oil hydrolysis. In a 18-point experimental design, FFA% of hydrolyzed <it>J. curcas </it>seed oil can be raised from 1.89% to 102.2%, which proved by FTIR and HPLC.</p

Overactive bladder – 18 years – part I

ABSTRACT Traditionally, the treatment of overactive bladder syndrome has been based on the use of oral medications with the purpose of reestablishing the detrusor stability. The recent better understanding of the urothelial physiology fostered conceptual changes, and the oral anticholinergics – pillars of the overactive bladder pharmacotherapy – started to be not only recognized for their properties of inhibiting the detrusor contractile activity, but also their action on the bladder afference, and therefore, on the reduction of the symptoms that constitute the syndrome. Beta-adrenergic agonists, which were recently added to the list of drugs for the treatment of overactive bladder, still wait for a definitive positioning – as either a second-line therapy or an adjuvant to oral anticholinergics. Conservative treatment failure, whether due to unsatisfactory results or the presence of adverse side effects, define it as refractory overactive bladder. In this context, the intravesical injection of botulinum toxin type A emerged as an effective option for the existing gap between the primary measures and more complex procedures such as bladder augmentation. Sacral neuromodulation, described three decades ago, had its indication reinforced in this overactive bladder era. Likewise, the electric stimulation of the tibial nerve is now a minimally invasive alternative to treat those with refractory overactive bladder. The results of the systematic literature review on the oral pharmacological treatment and the treatment of refractory overactive bladder gave rise to this second part of the review article Overactive Bladder – 18 years, prepared during the 1st Latin-American Consultation on Overactive Bladder

Does true Gleason pattern 3 merit its cancer descriptor?

Nearly five decades following its conception, the Gleason grading system remains a cornerstone in the prognostication and management of patients with prostate cancer. In the past few years, a debate has been growing whether Gleason score 3 + 3 = 6 prostate cancer is a clinically significant disease. Clinical, molecular and genetic research is addressing the question whether well characterized Gleason score 3 + 3 = 6 disease has the ability to affect the morbidity and quality of life of an individual in whom it is diagnosed. The consequences of treatment of Gleason score 3 + 3 = 6 disease are considerable; few men get through their treatments without sustaining some harm. Further modification of the classification of prostate cancer and dropping the label cancer for Gleason score 3 + 3 = 6 disease might be warranted

Grand Challenges in global eye health: a global prioritisation process using Delphi method

Background: We undertook a Grand Challenges in Global Eye Health prioritisation exercise to identify the key issues that must be addressed to improve eye health in the context of an ageing population, to eliminate persistent inequities in health-care access, and to mitigate widespread resource limitations. Methods: Drawing on methods used in previous Grand Challenges studies, we used a multi-step recruitment strategy to assemble a diverse panel of individuals from a range of disciplines relevant to global eye health from all regions globally to participate in a three-round, online, Delphi-like, prioritisation process to nominate and rank challenges in global eye health. Through this process, we developed both global and regional priority lists. Findings: Between Sept 1 and Dec 12, 2019, 470 individuals complete round 1 of the process, of whom 336 completed all three rounds (round 2 between Feb 26 and March 18, 2020, and round 3 between April 2 and April 25, 2020) 156 (46%) of 336 were women, 180 (54%) were men. The proportion of participants who worked in each region ranged from 104 (31%) in sub-Saharan Africa to 21 (6%) in central Europe, eastern Europe, and in central Asia. Of 85 unique challenges identified after round 1, 16 challenges were prioritised at the global level; six focused on detection and treatment of conditions (cataract, refractive error, glaucoma, diabetic retinopathy, services for children and screening for early detection), two focused on addressing shortages in human resource capacity, five on other health service and policy factors (including strengthening policies, integration, health information systems, and budget allocation), and three on improving access to care and promoting equity. Interpretation: This list of Grand Challenges serves as a starting point for immediate action by funders to guide investment in research and innovation in eye health. It challenges researchers, clinicians, and policy makers to build collaborations to address specific challenges. Funding: The Queen Elizabeth Diamond Jubilee Trust, Moorfields Eye Charity, National Institute for Health Research Moorfields Biomedical Research Centre, Wellcome Trust, Sightsavers, The Fred Hollows Foundation, The Seva Foundation, British Council for the Prevention of Blindness, and Christian Blind Mission. Translations: For the French, Spanish, Chinese, Portuguese, Arabic and Persian translations of the abstract see Supplementary Materials section

Re-assigning the DFNB33 locus to chromosome 10p11.23–q21.1

Homozygosity mapping is a powerful resource for mapping and identifying loci and genes responsible for autosomal recessive disorders. Nevertheless, it could result in the identification of several homozygous regions unrelated to the disease locus or non-informative regions. Previously, a genome-wide screen in a large consanguineous Jordanian family allowed us to assign the DFNB33 locus to chromosome 9q34.3. Sequencing of 23 candidate genes showed 11 SNPs in a heterozygous state in affected individuals. These results ruled out the candidate region on chromosome 9. Using additional markers, we were able to restrict the disease locus to an approximately 14 cM region at chromosome 10, located between markers D10S193 and D10S1784. A maximum LOD score of 3.99 was obtained with two markers, D10S199 and D10S220. The screening of two candidate genes, CX40.1 and FXYD4, failed to reveal any disease-causing mutations